Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8W31

Crystal structure of parkin (R0RB):2pUb with activator compound

これはPDB形式変換不可エントリーです。
8W31 の概要
エントリーDOI10.2210/pdb8w31/pdb
関連するPDBエントリー7US1
分子名称E3 ubiquitin-protein ligase parkin, Ubiquitin, ZINC ION, ... (6 entities in total)
機能のキーワードe3-ubiquitin ligase, ligase, activator
由来する生物種Rattus norvegicus (Norway rat)
詳細
タンパク質・核酸の鎖数3
化学式量合計44580.85
構造登録者
Sauve, V.,Gehring, K. (登録日: 2024-02-21, 公開日: 2024-08-21, 最終更新日: 2024-10-09)
主引用文献Sauve, V.,Stefan, E.,Croteau, N.,Goiran, T.,Fakih, R.,Bansal, N.,Hadzipasic, A.,Fang, J.,Murugan, P.,Chen, S.,Fon, E.A.,Hirst, W.D.,Silvian, L.F.,Trempe, J.F.,Gehring, K.
Activation of parkin by a molecular glue.
Nat Commun, 15:7707-7707, 2024
Cited by
PubMed Abstract: Mutations in parkin and PINK1 cause early-onset Parkinson's disease (EOPD). The ubiquitin ligase parkin is recruited to damaged mitochondria and activated by PINK1, a kinase that phosphorylates ubiquitin and the ubiquitin-like domain of parkin. Activated phospho-parkin then ubiquitinates mitochondrial proteins to target the damaged organelle for degradation. Here, we present the mechanism of activation of a new class of small molecule allosteric modulators that enhance parkin activity. The compounds act as molecular glues to enhance the ability of phospho-ubiquitin (pUb) to activate parkin. Ubiquitination assays and isothermal titration calorimetry with the most active compound (BIO-2007817) identify the mechanism of action. We present the crystal structure of a closely related compound (BIO-1975900) bound to a complex of parkin and two pUb molecules. The compound binds next to pUb on RING0 and contacts both proteins. Hydrogen-deuterium exchange mass spectrometry (HDX-MS) experiments confirm that activation occurs through release of the catalytic Rcat domain. In organello and mitophagy assays demonstrate that BIO-2007817 partially rescues the activity of parkin EOPD mutants, R42P and V56E, offering a basis for the design of activators as therapeutics for Parkinson's disease.
PubMed: 39300082
DOI: 10.1038/s41467-024-51889-3
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2.5 Å)
構造検証レポート
Validation report summary of 8w31
検証レポート(詳細版)ダウンロードをダウンロード

252456

件を2026-04-22に公開中

PDB statisticsPDBj update infoContact PDBjnumon